Log in or Sign up for Free to view tailored content for your specialty!
Cirrhosis/Liver Failure News
High out-of-pocket costs may lower rifaximin adherence for hepatic encephalopathy
Researchers reported low rifaximin treatment retention among patients with hepatic encephalopathy, with 30-day out-of-pocket treatment costs in excess of $150 among the factors associated with poor adherence.
Former Smash Mouth singer’s death underscores need for liver disease awareness
After nearly a decade of health problems, Steve Harwell, former lead singer and frontman for the band Smash Mouth, died Sept. 4 at age 56, which the band’s manager, Robert Hayes, said was caused by acute liver failure.
Log in or Sign up for Free to view tailored content for your specialty!
$9.5 million Novo Nordisk grant to fund trial of Ozempic, Wegovy for fibrosis in NAFLD
Novo Nordisk has awarded a $9.57 million grant supporting a clinical trial at the University of California San Diego NAFLD Research Center to evaluate the use of semaglutide in patients with fibrosis due to nonalcoholic fatty liver disease.
Higher animal protein intake increases mortality risk in cirrhosis by nearly fourfold
Higher intake of total and dairy protein and lower animal protein consumption correlated with a reduced risk for mortality among patients with cirrhosis, according to data published in BMC Gastroenterology.
Despite narrowing the gap, racial disparities persist in liver transplantation, mortality
Disparities in receipt of liver transplantation and mortality persisted over time among hospitalized Black and Hispanic patients with decompensated cirrhosis compared with their white counterparts, according to data in JAMA Network Open.
One-fifth of NASH patients develop cirrhosis in 4 years; lower risk for women, nonsmokers
Among patients with nonalcoholic steatohepatitis in the United States, 20% progressed to cirrhosis within 4 years, with female sex and nonsmoking status linked to lower risk for progression, according to data from the TARGET-NASH trial.
Use of simvastatin plus rifaximin not supported in patients with decompensated cirrhosis
Simvastatin plus rifaximin did not reduce progression to acute-on-chronic liver failure, complications from cirrhosis or risk for death in patients with decompensated cirrhosis, according to data presented at EASL Congress.
Only 25% of patients with cirrhosis receive transplant referrals at safety-net hospitals
Nearly 75% of patients with end-stage liver disease in safety-net hospitals were not referred for liver transplant evaluation, mostly due to active alcohol use or insurance issues, according to data published in JAMA Network Open.
VIDEO: ‘Clear correlation’ between IL-31, pruritus in primary biliary cholangitis
In a Healio video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on primary biliary cholangitis presented at EASL Congress, including risk factors for disease progression and seladelpar for treatment of pruritus.
Xarelto boosts survival for portal hypertension in cirrhosis without hike in bleeding risk
Xarelto improved portal hypertension complication-free survival in patients with cirrhosis and moderate liver dysfunction without an increase in major bleeding events, according to data presented at the EASL Congress.
-
Headline News
WikiGuidelines group publishes first new UTI guidance in 14 years
November 11, 20243 min read -
Headline News
Q&A: Industrial fires present unique respiratory health risks
November 11, 20244 min read -
Headline News
Physicians encouraged to conduct oral food challenges for infants, toddlers
November 12, 20247 min read
-
Headline News
WikiGuidelines group publishes first new UTI guidance in 14 years
November 11, 20243 min read -
Headline News
Q&A: Industrial fires present unique respiratory health risks
November 11, 20244 min read -
Headline News
Physicians encouraged to conduct oral food challenges for infants, toddlers
November 12, 20247 min read